Ling Tao
Latest contributions
REC-CAGEFREE II, NOTION-2, LANDMARK: Three major late-breaking trials presented at EuroPCR 2024
15 May 2024
The Course Directors have selected 3 major Late Breaking Trials (LBTs) that were presented for the first time during the 2024 edition of EuroPCR. These trials were selected on account of their design, outcomes and potential to influence daily clinical practice.
Major Late-Breaking Trials from EuroPCR 2024
15 May 2024 – From EuroPCR 2024
This session presents the latest results from major late-breaking trials presented at EuroPCR 2024. It covers a one-month DAPT followed by 5-month ticagrelor monotherapy in acute coronary syndromes with DCB, the first TAVI vs. SAVR randomised trial in younger low-risk patients with severe tricuspid or bicuspid...
Cutting-edge technologies: clinical updates on TES, BRS, TAVR and LAA closure
17 May 2023 – From EuroPCR 2023
Watch this session to find out more about the three-year outcomes of the FUTURE-II Trial, the TARGET clinical trial roadmap, the TARGET IV NA Trial update, the twelve-month outcomes of the SAVE PROTECT Trial, and the quantitative aortographic assessment of regurgitation in patients treated with VitaFlow.
Embrace the innovation in PCI and TAVR: Robocath R-One vascular robot for PCI in China, MicroPort Firehawk TES stent, and VitaFlow valve
18 May 2022 – From EuroPCR 2022
The objective of this EuroPCR 2022 session is to highlight MicroPort's innovation portfolio in 3 different fields: learn more about the clinical performance of Firehawk Family stent in STEMI patients evaluated by imaging tools, the features and benefits of PCI robot R-ONE and first clinical trial updates in China,...
